Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ampicillin + cloxacillin + lactic acid bacillus
- Development stage
- Unknown
- Lead developer
- Cyper Pharma
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Cypclox-LB is a fixed-dose combination antibiotic and probiotic product manufactured by Cyper Pharma. It contains ampicillin, a broad-spectrum aminopenicillin, and cloxacillin, a penicillinase-resistant penicillin, alongside lactic acid bacillus (Lactobacillus). The two antibiotics work synergistically to inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs); ampicillin provides coverage against a wide range of Gram-positive and Gram-negative bacteria, while cloxacillin is specifically effective against beta-lactamase-producing Staphylococci. Lactic acid bacillus is included as a probiotic to restore the natural intestinal microflora and prevent antibiotic-associated diarrhea, a common side effect of broad-spectrum antibiotic therapy. It is indicated for the treatment of various bacterial infections, including respiratory tract, skin, and soft tissue infections.
- Brand names
- Cypclox-LB
- Other names
- Ampicillin, Cloxacillin and Lactic Acid Bacillus Capsules
02
Targets
PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on ampicillin + cloxacillin + lactic acid bacillus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ampicillin + cloxacillin + lactic acid bacillus.